ADI-PEG 20 (pegargiminase)
Malignant Pleural Mesothelioma (Non-epithelioid)
Key Facts
About Polaris Pharma
Polaris Pharma is a clinical-stage biotech focused on developing first-in-class amino acid deprivation therapies for ASS1-deficient cancers. Its lead asset, ADI-PEG 20, has demonstrated pivotal Phase 3 success in malignant pleural mesothelioma and is under rolling BLA submission with the FDA, positioning the company for a potential near-term commercial launch. The strategy involves expanding the drug's utility across multiple oncology indications and exploring combinations with chemotherapy and immunotherapy to maximize its therapeutic and market potential.
View full company profileAbout Polaris Pharma
Polaris Pharma is a clinical-stage biotech focused on developing first-in-class amino acid deprivation therapies for ASS1-deficient cancers. Its lead asset, ADI-PEG 20, has demonstrated pivotal Phase 3 success in malignant pleural mesothelioma and is under rolling BLA submission with the FDA, positioning the company for a potential near-term commercial launch. The strategy involves expanding the drug's utility across multiple oncology indications and exploring combinations with chemotherapy and immunotherapy to maximize its therapeutic and market potential.
View full company profileAbout Polaris Pharma
Polaris Pharma is a clinical-stage biotech focused on developing first-in-class amino acid deprivation therapies for ASS1-deficient cancers. Its lead asset, ADI-PEG 20, has demonstrated pivotal Phase 3 success in malignant pleural mesothelioma and is under rolling BLA submission with the FDA, positioning the company for a potential near-term commercial launch. The strategy involves expanding the drug's utility across multiple oncology indications and exploring combinations with chemotherapy and immunotherapy to maximize its therapeutic and market potential.
View full company profileAbout Polaris Pharma
Polaris Pharma is a clinical-stage biotech focused on developing first-in-class amino acid deprivation therapies for ASS1-deficient cancers. Its lead asset, ADI-PEG 20, has demonstrated pivotal Phase 3 success in malignant pleural mesothelioma and is under rolling BLA submission with the FDA, positioning the company for a potential near-term commercial launch. The strategy involves expanding the drug's utility across multiple oncology indications and exploring combinations with chemotherapy and immunotherapy to maximize its therapeutic and market potential.
View full company profileAbout Polaris Pharma
Polaris Pharma is a clinical-stage biotech focused on developing first-in-class amino acid deprivation therapies for ASS1-deficient cancers. Its lead asset, ADI-PEG 20, has demonstrated pivotal Phase 3 success in malignant pleural mesothelioma and is under rolling BLA submission with the FDA, positioning the company for a potential near-term commercial launch. The strategy involves expanding the drug's utility across multiple oncology indications and exploring combinations with chemotherapy and immunotherapy to maximize its therapeutic and market potential.
View full company profileAbout Polaris Pharma
Polaris Pharma is a clinical-stage biotech focused on developing first-in-class amino acid deprivation therapies for ASS1-deficient cancers. Its lead asset, ADI-PEG 20, has demonstrated pivotal Phase 3 success in malignant pleural mesothelioma and is under rolling BLA submission with the FDA, positioning the company for a potential near-term commercial launch. The strategy involves expanding the drug's utility across multiple oncology indications and exploring combinations with chemotherapy and immunotherapy to maximize its therapeutic and market potential.
View full company profile